Multiple Sclerosis, 1 October 2002, vol. 8, no. 6, pp. 532-533(2)
Kalkers N.F.[1]; Barkhof F.[2]; Bergers E.[2]; van Schijndel R.[3];
Polman C.H.[1]
[1] Department of Neurology, Magnetic Resonance Centre for Multiple
Sclerosis Research, VU Medical Center, PO Box 7057, Amsterdam 1007 MB,
The Netherlands [2] Department of Radiology, Magnetic Resonance Centre
for Multiple Sclerosis Research, VU Medical Center, PO Box 7057, Amsterdam
1007 MB, The Netherlands [3] Department of Clinical Physics and Informatics,
Magnetic Resonance Centre for Multiple Sclerosis Research, VU Medical Center,
PO Box 7057, Amsterdam 1007 MB, The Netherlands
Progressive axonal loss is the most likely pathologic correlate of irreversible neurologic impairment in primary progressive multiple sclerosis.
In a run-in versus treatment trial, we show that the neuroprotective agent riluzole seems to reduce the rate of cervical cord atrophy and the development of hypointense T1 brain lesions on magnetic resonance imaging.